Lists of diseases

Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending August 31, 2022

Retrieved on: 
Friday, October 28, 2022

The delivery of therapeutics across the blood-brain barrier represents the final frontier in treating neurological disorders.

Key Points: 
  • The delivery of therapeutics across the blood-brain barrier represents the final frontier in treating neurological disorders.
  • The in-house development programs at Bioasis are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.
  • For more information about the Company, please visit www.bioasis.us .
  • Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement.

GIRLS, INC ATLANTA AND WITHERITE LAW GROUP TO HOST MENTAL HEALTH WORKSHOP FOR ATLANTA HIGH STUDENTS ON NATIONAL STRESS AWARENESS DAY

Retrieved on: 
Friday, October 28, 2022

ATLANTA, Oct. 28, 2022 /PRNewswire/ -- In recognition of National Stress Awareness Day, Witherite Law Group and 1-800-TruckWreck are donating $42,000 to Girls Incorporated of Greater Atlanta to fund mental health programs for youth in metro Atlanta, which includes providing licensed therapists at schools to provide counseling services. The Wellness program will kick-off on Tuesday, November 1, 2022 at 2 p.m. at Global Impact Academy, 155 Shaw Drive, Fairburn, GA 30213. The event will feature a mental health, stress awareness and emotional wellness workshop for 150 students, which will provide resources and tools for stress reduction, suicide prevention, bullying and other stressors that kids and teens face every day. The workshop will be led by Tristan Marsh, licensed therapist. There will also be remarks by Girls, Inc. CEO, Tiffany Collie-Bailey, followed by an official check presentation by Amy Witherite, founder of Witherite Law Group and 1-800-TruckWreck.

Key Points: 
  • There will also be remarks by Girls, Inc. CEO, Tiffany Collie-Bailey, followed by an official check presentation by Amy Witherite , founder of Witherite Law Group and 1-800-TruckWreck.
  • The mental health and social and emotional wellness program at Global Impact Academy is provided through programming funded by Witherite Law Group.
  • In 2021, Witherite Law Group donated $33,000 to Girls, Inc. of Greater Atlanta and this year they are donating $42,000.
  • "Educating youth, especially the next generation of leaders is a priority for our corporate culture at 1-800-TruckWreck and Witherite Law Group," said Amy Witherite.

Bionano Genomics Announces Extensive Lineup of Content at Association for Molecular Pathology (AMP) Annual Meeting Featuring OGM Utility Across Broad Range of Research Applications

Retrieved on: 
Friday, October 28, 2022

We are also pleased to see sessions and posters covering the combination of OGM with NGS data to provide a more comprehensive picture of the genome, commentedErik Holmlin, president and chief executive officer of Bionano.

Key Points: 
  • We are also pleased to see sessions and posters covering the combination of OGM with NGS data to provide a more comprehensive picture of the genome, commentedErik Holmlin, president and chief executive officer of Bionano.
  • Bionano Genomicsis a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine.
  • The Companys mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software.
  • The Company offers OGM solutions for applications across basic, translational and clinical research.

AC Immune Reports Third Quarter 2022 Financial Results and Provides a Corporate Update

Retrieved on: 
Friday, October 28, 2022

This bodes well for our wholly owned vaccine ACI-24.060, which targets the two most toxic forms of Abeta, soluble toxic Abeta oligomers and pyroglu-Abeta.

Key Points: 
  • This bodes well for our wholly owned vaccine ACI-24.060, which targets the two most toxic forms of Abeta, soluble toxic Abeta oligomers and pyroglu-Abeta.
  • Because ACI-24.060 is a vaccine, it also has the potential to offer safety, efficacy, and logistical advantages compared to monoclonal antibodies.
  • Interim results are expected around year end 2022 with plans to submit a U.S. Investigational New Drug (IND) application in Q1 2023.
  • Phase 1b safety and immunogenicity data readout in AD and decision to move into DS expected in Q4 2022.

Europe Artificial Tears (Cellulose, Glycerin, Oil-Based Emulsion, Polyethylene Glycol, Propylene Glycol) Market Research Report 2022-2028 - ResearchAndMarkets.com

Retrieved on: 
Friday, October 28, 2022

The "Europe Artificial Tears Market Research and Forecast 2022-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Europe Artificial Tears Market Research and Forecast 2022-2028" report has been added to ResearchAndMarkets.com's offering.
  • Although, innovations such as preservative-free artificial tears in artificial tears could be perceived as a major opportunity for the players engaged in the market.
  • Based on type, the market is segmented into cellulose-derived tears, glycerin-derived tears, oil-based emulsion tears, polyethylene glycol- & propylene glycol-based tears.
  • Insights about market determinants that are stimulating the European artificial tears market.

Global Plant-Based Food Market Report 2022: Rising Popularity of Plant-Based Meat and Seafood Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, October 28, 2022

In 2021, the global plant-based food market was valued at US$39.42 billion and is anticipated to grow to US$103.56 billion by 2027.

Key Points: 
  • In 2021, the global plant-based food market was valued at US$39.42 billion and is anticipated to grow to US$103.56 billion by 2027.
  • Food manufacturers ranging from startups to leading CPG companies are innovating rapidly in the plant-based food market.
  • By Type: The report provides the bifurcation of the plant-based food market into four segments based on type: Dairy, Meat, Egg, and Others.
  • The increased use of innovative technologies for product innovation, partnerships between domestic and international food companies, and rising government R&D expenditures in the food sector are the key factors driving the Asia Pacific plant-based food market.

Flare Therapeutics Presents Comprehensive Real-World Data in Advanced and Metastatic Urothelial Cancer in Support of Therapeutic Targeting of PPARG at 2022 EORTC-NCI-AACR Symposium

Retrieved on: 
Friday, October 28, 2022

Stratification of patients based upon their PPARG status serves as the foundation for our precision approach in identifying individuals most likely to respond to PPARG inhibition.

Key Points: 
  • Stratification of patients based upon their PPARG status serves as the foundation for our precision approach in identifying individuals most likely to respond to PPARG inhibition.
  • This disease has high rates of recurrence and the five-year survival rate is approximately 5% in metastatic cases.
  • The transcription factor peroxisome proliferator-activated receptor gamma (PPARG) is associated with the luminal lineage subtype reflecting approximately 65% of all advanced UC patients.
  • Flare Therapeutics is a biotechnology company pioneering a new therapeutic space with a novel approach to decipher the biology of transcription factors to develop small molecule medicines.

LISCure Biosciences Announces Oral Presentation of New Drug Candidate for NASH at Upcoming AASLD The Liver Meeting 2022

Retrieved on: 
Friday, October 28, 2022

SEOUL, South Korea, Oct. 28, 2022 /PRNewswire/ -- LISCure Biosciences, a clinical-stage biopharmaceutical company developing microbe-oriented new drugs based on innovative technologies, today announced that a new drug candidate for NASH was selected for an oral presentation at the American Association for The Study of Liver Diseases (AASLD) The Liver Meeting 2022, to be held November 4-8 in Washington DC. As part of the presentation, LISCure will become the first Korean biotech company accepted for an oral presentation at AASLD The Liver Meeting.

Key Points: 
  • As part of the presentation, LISCure will become the first Korean biotech company accepted for an oral presentation at AASLD The Liver Meeting.
  • Oral Presentation Date and Time: Monday, November 7, 2022, 4:30 PM
    AASLD is the leading global association in the liver disease field founded in 1950.
  • AASLD The Liver Meeting is an annual event in which more than 10,000 attendees - hepatologists, health professionals, and pharmaceutical industry - participate from around the world.
  • LISCure's new drug, a clinical-stage novel strain candidate, aims the "first-in-class" microbiome-based therapy for NASH and other liver diseases.

Numinus Launches Psychedelic-Assisted Therapy for Chronic and Serious Medical Illness

Retrieved on: 
Friday, October 28, 2022

"Chronic and serious medical illness encompasses a wide range of diagnoses, from terminal cancer to chronic pain.

Key Points: 
  • "Chronic and serious medical illness encompasses a wide range of diagnoses, from terminal cancer to chronic pain.
  • Numinus' program will offer ketamine-assisted therapy alongside additional community support, and has a targeted focus on improving patients' physical, emotional, mental and spiritual suffering caused by their illness.
  • Care will be provided by health care professionals who are specifically trained in chronic and serious medical illness.
  • "Many patients develop adjustment disorders, including depression and anxiety, as they go through the various stages of chronic and serious medical illness," said Dr. Paul Thielking (MD), Chief Science Officer, Numinus.

EQS-News: A New BioTech Research Race Is Focused On Improving Life For MS Patients

Retrieved on: 
Friday, October 28, 2022

As companies launch new products and research, government initiatives are projected to improve the accessibility of care and treatment.

Key Points: 
  • As companies launch new products and research, government initiatives are projected to improve the accessibility of care and treatment.
  • The rising MS numbers are believed to be the primary catalyst in market expansion.
  • Some are finding new research showing that an mRNA vaccine might also work in multiple sclerosis (MS).
  • Another recent article in Science showed published research that scientists have discovered about the risk of an individual contracting MS.